Sequenom, Inc., a life sciences company providing innovative testing and genetic analysis solutions, announced today its wholly owned subsidiary, Sequenom Laboratories, entered into an agreement to offer access to its MaterniT21™ PLUS laboratory-developed test to Mayo Medical Laboratories.
"We are delighted to expand our offerings to our national clients to offer the MaterniT21 PLUS test to physicians who have patients who are at high risk for fetal chromosomal abnormalities," says Dr. Franklin Cockerill, III, M.D, Chief Executive Officer of Mayo Medical Laboratories.
"Mayo Clinic is clearly committed to research, innovation and patient care, and we welcome this arrangement with them to expand access to our MaterniT21 PLUS test," said William Welch, President and COO of Sequenom, Inc.
Sequenom Laboratories was the first to market a noninvasive prenatal laboratory-developed test for fetal chromosomal aneuploidies. The MaterniT21 PLUS test analyzes the relative amount of 21, 18, 13, as well as X and Y chromosomal material in cell-free DNA. The test also reports additional findings for the presence of subchromosomal microdeletions and duplications which complement the MaterniT21 PLUS test core findings. The test is intended for use in pregnant women at increased risk for fetal chromosomal abnormalities and is indicated for use as early as 10 weeks' gestation. Estimates suggest there are about 750,000 pregnancies at high risk for fetal chromosomal abnormalities each year in the United States. The MaterniT21 PLUS test is available exclusively through Sequenom Laboratories as a testing service provided to physicians. To learn more about the test, please visit www.laboratories.sequenom.com.